Skip to main content
Equibles
ZNTL logo

ZNTL · Zentalis Pharmaceuticals, Inc.

Track ZNTL — free

Use ZNTL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ZNTL

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.56 -0.59 (-14.22%) At close · Aug 14
Market Cap
$255.15M
Shares
71.67M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.56 Open$3.53 Day$3.49–3.70 52W close$1.28–6.61 Avg vol 30d1.2M Short int5.6M · 7.8% float · 4.2d Short vol59% Last earningsFeb 27, 2024 DataApr 2020–Aug 2026 Filing10-Q · Aug 6

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +16%
above
Price vs 50-day avg −18%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 43%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −30%
trailing
6-month return +45%
trailing
YTD return +164%
this year
Relative strength +32%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.78% of float · ▼ -9.2% MoM · 4.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
113 holders — mid 3-yr range
Squeeze score 56
elevated · 0–100
Fundamentals
Fair
Revenue growth −100%
Y/Y
EPS growth +18%
Y/Y
Free cash flow $-125.2M
Balance sheet $36.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 130%
annualized · 1-yr
Max drawdown −47%
past year
ATR 11.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+16% Bullish
Price vs 50-day avg
−18% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
43% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.78% of float · ▼ -9.2% MoM · 4.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
113 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $4 · 43% Range high $7
vs 200-day avg +16% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and marketable securities $175M as of 6/30/26 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ZNTL
Zentalis Pharmaceuticals, Inc.
this stock
$255.15M +163.7% -100.0% — 7.8%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
113
% held
66.5%
Net QoQ
+3.7M sh
Top holder
5AM Venture Management, L…
Held Float
View
Held by Funds
Fund positions
49
View
Short & Settlement
Short Interest Falling
Shares short
5.6M
Days to cover
4.2d
Change
-568.1K sh
View
Short Volume
Short vol %
59%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
67
Value
$292
As of
Jul 2, 2026
View
Off-Exchange
Off-exchange %
32.2%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-137.1M
EPS diluted
$-1.91
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
17
View
Proposed Sales
Value
$1.4K
Shares
687
Filed
Feb 11, 2025
View
Earnings & Events
Earnings Calls
Last call
Jun 3, 2026
View
Investor Relations
Latest news
Zentalis Pharmaceuticals Announce…
Published
Aug 14, 2026
View

Performance

5D 20D 120D MTD YTD
ZNTL -15.6% -30.3% +45.3% -24.9% +163.7%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -16.0% -34.8% +31.5% -28.8% +149.9%
Key facts CIK 1725160 CUSIP 98943L107 13F (30d) 114 filings 111 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)